Trials / Recruiting
RecruitingNCT05933239
Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients
A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Universitair Ziekenhuis Brussel · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68GaNOTA-Anti-MMR-VHH2 | Injection of the radiopharmaceutical and PET/CT imaging |
Timeline
- Start date
- 2023-03-30
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2023-07-06
- Last updated
- 2024-06-17
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05933239. Inclusion in this directory is not an endorsement.